首页> 外文期刊>Leukemia >Validation of BIOMED-2 multiplex PCR tubes for detection of TCRB gene rearrangements in T-cell malignancies
【24h】

Validation of BIOMED-2 multiplex PCR tubes for detection of TCRB gene rearrangements in T-cell malignancies

机译:验证BIOMED-2多重PCR管用于检测T细胞恶性肿瘤中TCRB基因重排

获取原文
       

摘要

The BIOMED-2 Concerted Action BMH4-CT98-3936 on 'Polymerase chain reaction (PCR)-based clonality studies for early diagnosis of lymphoproliferative disorders' developed standardized PCR protocols for detection of immunoglobulin (Ig) and T-cell receptor (TCR) rearrangements, including TCR beta (TCRB). As no comparable TCRB PCR method pre-existed and only a limited number of samples was tested within the BIOMED-2 study, we initiated this study for further validation of the newly developed TCRB PCR approach by comparing PCR data with previously generated Southern blot (SB) data in a series of 66 immature (ALL) and 36 mature T-cell malignancies. In 91% of cases, concordant PCR and SB results were found. Discrepancies consisted of either failure to detect SB-detected TCRB rearrangements by PCR (6.5%) or detection of an additional non-SB defined rearrangement (2.5%). In 99% of cases (99/100), at least one clonal TCRB rearrangement was detected by PCR in the SB-positive cases. A predominance of complete V-J rearrangements was seen in TCR+ T-cell malignancies and CD3-negative T-ALL (100 and 90%, respectively), whereas in TCR+ T-ALL, more incomplete D-J TCRB rearrangements were detected (73%). Our results underline the reliability of this new TCRB PCR method and its strategic applicability in clonality diagnostics of lymphoproliferative disorders and MRD studies.
机译:针对基于“聚合酶链反应(PCR)的克隆性研究以早期诊断淋巴增生性疾病”的BIOMED-2协同行动BMH4-CT98-3936开发了用于检测免疫球蛋白(Ig)和T细胞受体(TCR)重排的标准化PCR方案,包括TCR beta(TCRB)。由于没有预先存在可比的TCRB PCR方法,并且在BIOMED-2研究中仅测试了有限数量的样品,因此我们通过将PCR数据与先前生成的Southern blot(SB)进行比较来启动该研究以进一步验证新开发的TCRB PCR方法)收集的一系列66例未成熟(ALL)和36例成熟T细胞恶性肿瘤中的数据。在91%的病例中,PCR和SB结果一致。差异包括无法通过PCR检测SB检测到的TCRB重排(6.5%)或检测到其他非SB定义的重排(2.5%)。在99%的病例中(99/100),在SB阳性病例中,通过PCR检测到至少一个克隆TCRB重排。在TCR + T细胞恶性肿瘤和CD3阴性T-ALL中(分别为100和90 %),可以看到完全VJ重排的优势,而在TCR + T-ALL中,检测到更不完整的DJ TCRB重排(73%)。 。我们的结果强调了这种新的TCRB PCR方法的可靠性及其在淋巴增生性疾病的克隆性诊断和MRD研究中的战略适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号